

comprising the parenteral administration of a pure solid state of the (-)-enantiomer of 5-methoxy-2[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in either its non-salt or alkaline salt form, as the active ingredient and a pharmaceutically acceptable carrier.

CONCLUSION

Applicants submit that claims 35-51 are in condition for allowance and, therefore, allowance of the claims is respectfully requested.

Any additional fees due in connection with this response should be charged to Deposit Account No. 23-1703.

Dated: October 15, 1999

Respectfully submitted,



John M. Genova
Reg. No. 32,224
Attorney for Applicants

White & Case LLP
Patent Department
1155 Avenue of the Americas
New York, NY 10036-2787
(212) 819-8200

